Abstract:<p>Depression, anxiety and psychotic disorders are common perinatal mental health disorders in the postpartum period. Depressive symptoms that occur postpartum are also present in the prenatal period in 50% of patients. Risk factors for the development of postpartum depression include poor relationship with the partner, lack of social support, mother’s low socioeconomic status and multiparity. It has been determined that reproductive hormones change significantly during peripartum. Progesterone is one of these hormones and acts on the central nervous system starting from the fetal period; neurogenesis, neuromodulation, sedation are some of these effects. It has also been observed that progesterone has positive effects on learning, memory and mood. Progesterone exerts its effects on the central nervous system by converting into its metabolite allopregnanolone. Allopregnanolone is one of the neuroactive steroids, and found in similar amounts in the circulation of pregnant women and fetuses. It acts on synaptic and extrasynaptic γ-aminobutyric acid type A (GABAA) receptors and is a positive allosteric modulator of the GABAA receptor. Allopregnanolone increases both the receptor’s opening frequency and its open duration and improves GABAergic current. Low serum allopregnanolone levels in the second trimester are predictive of postpartum depression. Each 1 ng/mL increase in serum allopregnanolone level reduces the risk of development of postpartum depression by 63%. Brexanolone and zuranolone are synthetic allopregnanolone preparations approved by the FDA for use in female patients with postpartum depression. They act via positive allosteric modulation on the GABAA receptor. Brexanolone is administered via intravenous infusion at varying infusion rates in a healthcare facility over 60 hours. Its effect starts immediately after treatment and continues until the 30th day of follow-up, and depressive mood does not recur. Zuranolone was developed for oral use, and administered as a single dose of 50 mg after a fatty meal. Their effectiveness has been demonstrated in patients with treatment-resistant depression. The development of other novel agents that act on the GABAA receptor and other pathways for the treatment of postpartum depression is in progress.</p>.

Transformative Therapies for Depression: Postpartum Depression, Major Depressive Disorder, and Treatment-Resistant Depression

Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development

Advances in treatment for postpartum major depressive disorder

Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions

An update on approved and emerging drugs for the treatment of postpartum depression

Pharmacological approaches to the challenge of treatment-resistant depression

New and emerging treatments for major depressive disorder

An update on the pharmacotherapy of postpartum depression

Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD)

Treating Postpartum Depression With Brexanolone in a Specialty Hospital

Emerging drugs for the treatment of major depressive disorder

Understanding and treating postpartum depression: a narrative review

Alternative Treatments for Postpartum Depression

The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis

Exploring the clinical potentials of zuranolone in managing postpartum depression: A new therapeutic horizon

Critical review and recommendations for enhancement of the article on novel neurosteroid therapeutics for postpartum depression

Brexanolone, a GABAA Modulator, in the Treatment of Postpartum Depression in Adults: A Comprehensive Review

Clinical pharmacological innovation in the treatment of depression

Brexanolone Treatment in a Real-World Patient Population

Treatment of postpartum depression, part 1: a critical review of biological interventions

New paradigms for treatment-resistant depression.